265. 脂肪萎縮症
[臨床試験数:109,薬物数:164(DrugBank:59),標的遺伝子数:26,標的パスウェイ数:94

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04159415
(ClinicalTrials.gov)
January 7, 20207/11/2019Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyA Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyGeneralized LipodystrophyDrug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461Regeneron PharmaceuticalsNULLActive, not recruiting12 YearsN/AAll26Phase 2United States